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The aim of this study was to investigate initiation of and persistence with warfarin treat-
ment in patients with atrial ﬁbrillation (AF) according to ethnicity. Patients hospitalized with
ﬁrst-time AF from 1997 to 2009, prescription claims of warfarin and country of birth were
identiﬁedbyindividual-levellinkageofnationwideadministrativeagencies.Coxproportional
hazards models were used to estimate the relationship between covariates affecting initia-
tionandnon-persistencewithwarfarintreatment.Atotalof151,537patientswereincluded
in the study and 5,061(3.3%) were of non-Danish origin. CHADS2 score distribution varied
substantiallyaccordingtoethnicity,theproportionofpatientswithCHADS2score1being
79.2, 78.1, 65.9, and 46.0% for patients of Danish, Western, Eastern, and African origin,
respectively. 79,239(52.4%) of all patients initiated treatment with warfarin at some point
in time. Multivariable Cox proportional hazard analyses indicated patients of Eastern and
African origin were less likely to initiate warfarin therapy (HR 0.75; 95% CI 0.69–0.82 and
HR 0.58; 95% CI 0.44–0.76, respectively). Patients of Eastern origin were more likely to
interrupt treatment (HR 1.23; 95% CI 1.02–1.47; for all patients; HR 1.62; 95% CI 1.22–2.16;
for patients with CHADS2 score >1).African origin was associated with a trend to interrupt
treatment (HR 1.44; 95% CI 0.46–4.47; for patients with CHADS2 score >1). Initiation of
and persistence with warfarin inAF patients is lower among patients of Eastern andAfrican
origin compared to patients of Danish and Western origin, despite equal access to health
care and medication. Future studies should address, beyond ethnicity, all possible driving
factors of (non)initiation and persistence with treatment in general.This will be particularly
interesting in light of the new generation of anticoagulants, which might render different
adherence to treatment.
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INTRODUCTION
Patientswithatrialﬁbrillation(AF)areatincreasedriskof throm-
boembolism and stroke, and the beneﬁt from vitamin K antago-
nists (VKA) for stroke prevention in AF patients has been exten-
sively documented (Hughes and Lip, 2008; Camm et al., 2010;
Olesen et al., 2011). Consequently,VKA therapy is recommended
for patients with AF who have additional risk factors for stroke.
However, substantial underuse of VKA has been reported in spite
of existing guidelines (Ogilvie et al.,2010).
The clinical and economic consequences of under using VKA
therapy are profound and understanding factors that determine
VKA use may improve the quality of care for patients with AF.
This is of particular interest in light of the new generation of
anticoagulants that may render different adherence to treatment.
Ethnicityhasbeenassociatedwithdifferencesincardiovascular
health parameters and clinical outcomes (Balarajan,1991; Benner
et al., 2002; Kaplan et al., 2004; Hertz et al., 2007; Harding et al.,
2008; Cooper et al., 2009; McWilliams et al., 2009; Dominguez
et al., 2010; Hempler et al., 2010), even when differences in socio-
economic proﬁles are equalized (Mayberry et al., 2000; Trivedi
et al.,2006; Hertz et al.,2007; Hozawa et al.,2007).
LimiteddatahasbeenpublishedconcerningtheuseofVKAfor
patients with AF according to ethnicity (Lip et al., 1998; Schauer
et al., 2007). Thus, more comprehensive analyses are needed to
identify possible underuse of VKA in ethnic groups in order to
deﬁne targets for improvement in anticoagulation treatment.
The aim of this study was to investigate the initiation of and
persistencetowarfarintreatmentaccordingtoethnicityinpatients
with ﬁrst-time AF hospitalization between 1997 and 2009.
MATERIALS AND METHODS
All permanent residents in Denmark have a unique civil regis-
tration number which enables linkage between national registries
on an individual basis. The cohort of patients selected for this
study was identiﬁed using the Danish National Patient Registry,
which has kept records of all hospitalizations in Denmark since
1978. All patients hospitalized with ﬁrst-time AF [International
Classiﬁcation of Diseases,10th revision (ICD-10),code I48,Inter-
national Classiﬁcation of Diseases, 8th revision (ICD-8), code
42793, 42794] as a primary or secondary diagnosis between 1997
and2009wereidentiﬁed.Patientsaged30yearswereincludedin
the analyses. Since drug treatment may be altered during hospital
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admission, follow-up initiated 7days after discharge (index date).
Patientswhodiedwithin7daysafterdischargewereexcludedfrom
the study.
For the present study, SAS statistical software version 9.2 was
used for data collection.
ETHNICITY
The main concern was to address cultural and not racial ethnicity.
To take the effect of cultural legacy into consideration, we con-
structed a more reﬁned ethnicity proxy,“country of origin,”based
on theparents’countryof birth fora given individual.Two simple
ethnicity parameters were used, country of birth and citizenship.
To be considered of Danish origin, the subject needed at least
one parent who was born in Denmark and who holds Danish cit-
izenship, regardless of the subject’s own citizenship or country of
birth.Personswhoseparentsdidnotfulﬁllthesecriteriawereclas-
siﬁed as being of “non-Danish origin.” The patient’s country of
origin was then deﬁned by the mother’s country of birth, if data
were available and if not,by the individual’s own country of birth.
Countries were grouped into four categories to form four large
ethnic origins: (1)“Danish origin”as explained above; (2)“West-
ernorigin”whichincludedBalticcountries,theAmericas,Oceania,
and most European countries other than Denmark; (3) “Eastern
countries”which included all countries from the Asian continent
and countries from Eastern Europe considered to be more cul-
turally related to Asia including Turkey, Russia, Slovakia, Czech
republic, Ukraine, and Belarus; and (4) “African origin” which
included all countries from the African continent, as described in
detail previously (Dominguez et al., 2010).
MEDICAL TREATMENT
Information on the use of pharmacotherapy was obtained from
the Registry of Medicinal Product Statistics (national prescription
registry) that has existed since 1995. The registry keeps informa-
tion about all prescriptions dispensed from Danish pharmacies
including prescribed drugs, date of dispensing, strength, quantity
dispensed,andtheafﬁliationofthedoctorissuingtheprescription.
Eachprescribeddrugiscodedaccordingtoaninternationalclassi-
ﬁcation of pharmaceuticals, the anatomical therapeutic chemical
(ATC) classiﬁcation. The registry has been found to be accurate
and has been described in more detail previously (Gaist et al.,
1997). Warfarin was identiﬁed using the ATC code B01AA03. All
subjects who claimed a prescription of warfarin during the period
1997–2009 were identiﬁed. Initiation of treatment was registered
inrelationtotheindexdate.Wedeﬁnednon-persistenceasabreak
in treatment of 90days or more based on previous ﬁndings that
patientswhointerruptedtheirtreatmentforlessthan90dayswere
prone to re-initiate treatment (Gislason et al., 2006).
CO-MORBIDITY – THROMBOEMBOLIC RISK ASSESSMENT
Patients who claimed a prescription for a glucose lowering
drug (A10) were deﬁned as having diabetes mellitus. We iden-
tiﬁed patients with hypertension from combination treatment
with at least two of the following classes of antihypertensive
drugs: a adrenergic blockers (C02A, C02B, C02C), non-loop-
diuretics (C02DA, C02L, C03A, C03B, C03D, C03E, C03X, C07C,
C07D, C08G, C09BA, C09DA, C09XA52), vasodilators (C02DB,
C02DD, C02DG, C04, C05), b-blockers (C07), calcium channel
blockers (C07F, C08, C09BB,C09DB), and renin-angiotensin sys-
tem inhibitors (C09). This deﬁnition of hypertension has been
well validated with a high speciﬁcity and sensitivity, as previously
described in detail (Ekholm et al., 2009; Olesen et al., 2011).
Previous thromboembolism and vascular disease were iden-
tiﬁed through the national patient registry. Thromboembolism
was deﬁned as peripheral artery embolism, stroke and transient
ischemic attack (433–438, 444, G458, G459, I63, I64, I74), and
vascular disease was deﬁned as ischemic heart disease, peripheral
artery disease, and aortic plaque (410–414, 440, I21, I22, I700,
I702–709; Madsen et al., 2003; Krarup et al., 2007; Joensen et al.,
2009; Lip et al., 2010; Severinsen et al., 2010).
Congestiveheartfailurewasdeﬁnedasthecombinationof pre-
vious diagnoses of heart failure, registered in the national patient
registry under the following codes 425, 4270, 4271, I110, I42, I50,
J819, and treatment with loop-diuretics (C03C; Kumler et al.,
2008).
The CHADS2 score was calculated by adding one point each
for heart failure, hypertension, age 75, diabetes, and two points
for previous thromboembolism. Thus,the score ranged from 0 to
6 (Gage et al., 2001).
VITAL STATUS
Informationabouteachpatient’svitalstatuswasobtainedthrough
the Civil Registration System which records all cases of death
within 2weeks.
STATISTICAL ANALYSIS
The relationship between time from index date (discharge date
plus 7days) to initiation of therapy and time to ﬁrst break in
therapy of 90days or more were evaluated with Kaplan–Meier
estimators(censoredfordeath).Coxproportionalhazardsmodels
wereusedtoestimatetherelationshipbetweencovariatesaffecting
initiation and non-persistence with warfarin treatment. Time to
ﬁrst break in therapy of 90days or more was tested in two analy-
ses.We performed the ﬁrst analysis without inclusion of CHADS2
score. Since patients with a low CHADS2 score (0–1) do not nec-
essarily require long-term VKA therapy, for example in case of
cardioversion, the analysis was repeated including only patients
with CHADS2 score >1, in attempt to exclude from the analysis
patients with intentional interruption of treatment. All models
were adjusted for gender, age, ethnicity, and CHADS2 score.
WeusedSASstatisticalsoftwareversion9.2andStatastatistical
software version 11.0 for the analyses.
ETHICS
This study was approved by the Danish Data Protection Agency
(No. 2008-41-2685). Retrospective register-based studies do not
require ethical approval in Denmark. Data collection, handling,
andanalyseswereonlyaccessiblethroughDenmarkStatistics.The
civil registration number, used for the individual-level linkage of
the different registries, was encrypted to the researches.
RESULTS
A total of 163,234 patients were hospitalized with ﬁrst-time AF
in Denmark between 1997 and 2009, 151,553 of which were aged
30years and survived 7days after discharge. Due to uncertain
ethnic origin, 16 patients were excluded. Hence, 151,537(92.7%)
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patients were included in the analyses. Baseline characteristics of
thepopulationstratiﬁedbytheethnicityproxy“countryof origin”
are shown in Table 1.
TheAF population comprised of 3.3% patients of non-Danish
origin, of which 2.5, 0.8, and 0.1% were of Western, Eastern,
and African origin, respectively. The corresponding distribution
of persons of non-Danish origin (5.9% of total population of
Denmark) was 3.0% Western, 2.5% Eastern, and 0.4% of African
origin,asof December31st,2009.Thesmallamountof patientsof
Africanorigin(n D126)leadstopowerreduction,generallyresult-
ing in wider conﬁdence intervals and higher p-values associated
with African origin, meaning the results regarding this subgroup
should be interpreted with caution.
There were considerable differences in thromboembolic risk
factors of the cohort according to ethnicity (Table 1). The group
of Western origin had similar characteristics to the group of Dan-
ish origin. Patients of Eastern and African origin were on average
more than 10years younger while only 21.3% of patients of East-
ernoriginand8.7%of patientsofAfricanoriginwere75years-old
or older. The younger age of AF patients of Eastern and African
origin reﬂected well the age of the overall population of Eastern
and African origin in Denmark, since the average age was 49 and
48years for persons of Eastern and African origin, respectively,
in contrast to 59years for persons of Western and Danish ori-
gin. Patients of African origin had considerably less co-morbidity
except from diabetes. The group of Eastern origin had the same
prevalenceofhypertension,lowerprevalenceofheartfailure,anda
higher prevalence of diabetes and previous ischemic heart disease
compared to patients of Western and Danish origin. The over-
all difference in co-morbidity status and age between the ethnic
groupsresultedinaheterogeneousdistributionof CHADS2 score,
which is illustrated in Figure1. Among patients of Danish origin,
79.2%hadaCHADS2 scoreof oneormoreincontrastto65.9and
46.0% of the Eastern and African populations, respectively. The
results did not differ when using country of birth as the ethnicity
proxy.
Atotalof 79,239(52.4%)of allpatientsinitiatedtreatmentwith
warfarinatsomepointintime.Theresultswereonlyslightlydiffer-
ent when stratiﬁed by ethnicity. Of those who initiated treatment,
26,769(33.8%) initiated before admission, 31,973(40.3%) did so
within the ﬁrst 7days after discharge, and 20,497(25.9%) more
than 7days after discharge. Patients of Eastern origin were less
likely to initiate treatment than patients of Western and Danish
origin (HR 0.75; 95% CI 0.69–0.82, p <0.0001) as were patients
ofAfricanorigin(HR0.58;95%CI0.44–0.76,p <0.0001;Table2;
Figure 2).
Patients of Eastern origin were more prone to interrupt treat-
ment compared to patients of Danish origin, since they had a
higher hazard ratio to break in treatment of 90days or more
(Table 3). These results were found both in the analyses includ-
ing all patients (HR 1.23; 95% CI 1.02–1.47, p D0.03) and in the
analyses that only included patients with CHADS2 score >1 (HR
1.62; 95% CI 1.22–2.16, p D0.001). African origin was associated
with a trend to interrupt treatment (HR 1.44; 95% CI 0.46–4.47,
p D0.53) in the analysis including patients who have CHADS2
score >1, but the results were not statistically signiﬁcant. Table 3
shows the results of a multivariable Cox proportional hazard
analysis of time to ﬁrst break of at least 90days in Warfarin treat-
ment,asproxyfornon-persistence,forthedifferentethnicgroups.
Figure3showslong-termpersistencetowarfarintherapystratiﬁed
by ethnic origin.
DISCUSSION
This study indicates that patients of Asian andAfrican origin with
AF are at increased risk of not initiating and of discontinuing
adequate warfarin treatment.
Few studies have been published on initiation of and persis-
tencetotreatmentof cardiovasculardiseaseaccordingtoethnicity.
Table 1 | Baseline characteristics.
Characteristics All origins Danish origin Non-Danish origin
Western origin Eastern origin African origin
Total patients 151,537 (100%) 146,492 (96.7%) 3,786 (2.5%) 1,133 (0.8%) 126 (0.1%)
Females 71,320 (47 .1%) 68,633 (46.9%) 2,125 (56.1%) 527 (46.5%) 35 (27 .8%)
Mean age at presentationSD*, years 73.6 (12.4) 73.7 (12.3) 73.1 (12.6) 63.8 (13.5) 56.9 (13.4)
Age 75 77 ,765 (51.3%) 75,647 (51.6%) 1,866 (49.3%) 241 (21.3%) 11 (8.7%)
Heart failure 33,772 (22.3%) 32,738 (22.4%) 796 (21.0%) 223 (19.7%) 15 (11.9%)
Hypertension 69,315 (45.7%) 67 ,078 (45.8%) 1,692 (44.7%) 500 (44.1%) 45 (35.1%)
Diabetes 13,829 (9.1%) 13,204 (9.0%) 376 (9.9%) 231 (20.4%) 18 (14.3%)
Previous stroke/TCI 23,505 (15.5%) 22,806 (15.6%) 566 (15.0%) 122 (10.8%) 11 (8.7%)
Previous IHD 33,985 (22.4%) 32,763 (22.4%) 880 (23.2%) 326 (28.8%) 16 (12.7%)
CHADS2 score 1 119,834 (79.1%) 116,074 (79.2%) 2,955 (78,1%) 747 (65.9%) 58 (46.0%)
Warfarin treatment 79,239 (52.3%) 76,711 (52.4%) 1,915 (50.6%) 556 (49.1%) 57 (45.2%)
Patients admitted with ﬁrst-time atrial ﬁbrillation from 1997 to 2009. Patients are divided into four ethnic groups: (1) Danish origin, (2) Western origin, (3) Eastern
origin, and (4) African origin.
*SD, standard deviation; CHADS2 score of 1 or more includes those patients with at least one of the following.
Baseline characteristics; congestive heart failure, hypertension, 75 or more years of age, or stroke.
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FIGURE 1 | CHADS2 scores distribution for all patients and divided into four ethnic groups: Danish origin, Eastern origin,Western origin,African origin.
Table 2 | Multivariate Cox logistic regression analysis: hazard ratio for
initiation of warfarin treatment for patients discharged with ﬁrst-time
atrial ﬁbrillation in the period 1997–2009 stratiﬁed by ethnic origin.
Patient
origin
N Dnumber of
patients
Hazard
ratio
95% Conﬁdence
interval
p-Value
Danish 146,492 1.00
Eastern 1,133 0.75 0.69–0.82 <0.0001
Western 3,786 0.95 0.91–1.00 0.04
African 126 0.58 0.44–0.76 <0.0001
All models were adjusted for gender, age, ethnicity, and CHADS2 score.
The existing data suggests ethnic minorities are likely to be under-
treated (Lip et al., 1998; Schauer et al., 2007; Dominguez et al.,
2010; Hempler et al.,2010). To our knowledge,none of the previ-
ous studies have investigated AF patients’ compliance to warfarin
therapy according to ethnicity. One previous study has exam-
ined adherence to warfarin therapy in American patients with
AF according to race (African American/Whites), and found the
minority to be undertreated (Schauer et al., 2007). There are no
such studies in Europe. Our ﬁndings that Eastern and African
origin are associated with inadequate warfarin therapy in a popu-
lation of patients with AF complement earlier studies that found
Eastern and African origin associated with inadequate treatment,
inpatientswithpreviousacutemyocardialinfarctionanddiabetes
(Lip et al., 1998; Dominguez et al., 2010; Hempler et al., 2010;
Jenum et al., 2012).
Initiation of and persistence to treatment may be inﬂuenced
by any number of factors such as socio-economic status (SES)
and doctor-patient relationship (Schouten and Meeuwesen,2006;
Batesetal.,2009).Previousstudiesthatexaminedtherapycompli-
anceaccordingtoethnicityinDenmarkhavenotfoundhousehold
incometoinﬂuencecompliance(Dominguezetal.,2010;Hempler
et al.,2010). This could be due to high social equality,equal access
tohealthcareandeducationalsystems,alongwithreimbursement
for medical expenses for all residents in Denmark. However, eth-
nic background has been associated with differences in treatment
and outcome, even when SES was found signiﬁcant and adjusted
for (Mayberry et al., 2000; Trivedi et al., 2006; Hertz et al., 2007;
Hozawa et al., 2007; Kagawa-Singer et al., 2010).
Divergent cultural/ethnic backgrounds between doctor and
patient have been associated with worse doctor-patient relation-
ship, even after adjusting for socio-economic variables (Schouten
and Meeuwesen,2006; Kagawa-Singer et al.,2010). Several factors
have been proposed to explain the relationship between doctors
and patients from different ethnic/cultural backgrounds. Among
these factors,language has been the most commonly addressed in
the literature, since it poses challenges to doctor-patient commu-
nication and thereby induces non-compliance. However, doctor-
patient relationship comprises aspects other than language skills,
possibly even more so, when it comes to individuals with dif-
ferent cultural backgrounds (Schouten and Meeuwesen, 2006).
Aspects like perceptual bias, i.e., how an individual with a certain
origin is perceived by the doctor and vice-versa, and the patient’s
preference for different types of doctor-patient relationships are
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FIGURE 2 | Patients who were admitted with ﬁrst-time atrial ﬁbrillation, alive 7days after discharge and have claimed a prescription of warfarin.
Kaplan–Meier plots over time from ﬁrst-admission with atrial ﬁbrillation until ﬁrst warfarin claim, stratiﬁed by ethnic origin. Curves end when all patients have
been censored.
Table 3 | Multivariable Cox logistic regression analysis: time to ﬁrst break of 90Days in warfarin treatment according to ethnicity.
Patient origin All patients (CHADS2 scoreD0–6) CHADS2 score >1
N Dnumber of
patients
Hazard
ratio
95% Conﬁdence
interval
p-Value N Dnumber of
patients
Hazard
ratio
95% Conﬁdence
interval
p-Value
Danish 76,711 1.00 36,308 1.00
Eastern 556 1.23 1.02–1.47 0.03 235 1.62 1.22–2.16 0.001
Western 1915 1.13 1.01–1.26 0.04 876 1.15 0.96–1.39 0.13
African 57 1.03 0.55–1.91 0.93 19 1.44 0.46–4.47 0.53
On the left is the analysis including all patients and on the right the analysis including only patients with CHADS2 score >1.This was done so to take into consideration
patients who had the indication for treatment with VKA for a limited period of time, since these patients would discontinue treatment because they should and not
because of poor compliance. All models were adjusted for gender, age, ethnicity, and CHADS2 score.
also paramount and should be taken into account when analyzing
doctor-patient communication (Stavropoulou, 2011).
Due to warfarin’s narrow therapeutic range, numerous inter-
actions and bleeding risk, warfarin therapy requires numerous
control visits, blood tests, and continuous adjustment of dosage.
Thus, it certainly demands clear understanding between doc-
tor and patient. As mentioned above, doctor-patient relationship
reliesonanumberof differentaspects,allof whichinﬂuencecom-
pliancetomedicaltherapy.Divergentcultural/ethnicbackgrounds
between doctor and patient might introduce several aspects, such
as language skills and perceptual bias that could lead to a prob-
lematic doctor-patient relationship. This could, at least in part,
explain why AF patients of African and Eastern origin were prone
not to receive proper warfarin treatment, in spite of equal access
to the health care system. In an increasingly globalized world with
multicultural societies, it has become of paramount importance
to understand multicultural doctor-patient relationships and the
mechanisms of importance to initiation of and persistence with
treatment. Further research is needed to explore and address
the causes of (non)initiation of and persistence with treatment.
This will be particularly interesting in light of the new genera-
tion of anticoagulants, since these require less control, may be
less demanding on doctor-patient relationship and thus improve
adherence to treatment.
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FIGURE 3 | Persistence with warfarin treatment stratiﬁed by ethnicity, in
patients who were admitted with ﬁrst-time atrial ﬁbrillation in the
period 1997–2009. Each point represents the number of patients with
available medication divided by the number of patients alive at that time.
The lower incidence of AF among ethnic minorities could be
due to the markedly younger age of these groups in the overall
population,sinceAF increases with age (prevalence<0.5% in age
group 40–50years; Camm et al., 2010). The majority of previ-
ous AF studies rely on Caucasian populations, yielding limited
epidemiological data about AF incidence/prevalence and throm-
boembolic risk factors in non-Caucasian populations. However,
our ﬁndings are in accordance with those of studies conducted
in the primary care sector in England and among African Ameri-
cans in the United States, that also have found lower AF preva-
lence/incidence among ethnic minorities and different throm-
boembolic risk proﬁles among ethnic groups (Lip et al., 1998;
Gbadebo et al., 2011; Gill et al., 2011).
The main strength of our study is that it is a nationwide study
that includes information about all hospital admissions in Den-
mark since 1978 and the ﬁrst nationwide study of AF patients
according to ethnicity. Furthermore, the diagnosis of AF, which
was used as inclusion criteria, has a very high positive predictive
value (99%; Frost et al., 2007). Additionally, data on prescription
claims have been proven accurate in other studies (Gaist et al.,
1997). Finally, selection bias is unlikely to play a signiﬁcant role,
sinceallcitizensinDenmarkhavefreeandequalaccesstoageneral
practitioner and hospital care regardless of SES.
The main limitation of the study is its observational and retro-
spective nature which can lead to misclassiﬁcation and inclusion
bias. Our population includes only patients with hospital admit-
tance which inevitably restricts the population of patients with
AF. Risk factors and co-morbidity are probably underestimated,
since diabetes, heart failure, and hypertension were diagnosed by
prescription claims, thereby excluding patients who hold these
diagnoses but are treated with lifestyle interventions alone or who
do not purchase medications. The relative lower prevalence of
co-morbidity and thereby lower CHADS2 score for patients of
non-Danishorigincould,inpart,beduetoalargeramountofnon-
Danish patients who are not receiving medications for diabetes,
heart failure, and hypertension. It is also not possible to establish
contraindications for treatment with warfarin in our study,which
leadstoincludepatientswhointerruptwarfarintreatmentbecause
of relevantcontraindicationsinouranalyses,aspatientswithpoor
persistence to warfarin treatment.
Our main goal was to address patient adherence to warfarin
therapyaccordingtoethnicity,amongpatientswithAF.Ourstudy
found ethnic minorities undertreated, which also has been found
in other disease populations (Schouten and Meeuwesen, 2006;
Dominguezetal.,2010;Hempleretal.,2010;Kagawa-Singeretal.,
2010). However, since there is no consensus as to how to address
ethnicity, it is done so in various ways in the literature, using
race, country of birth, or cultural background as ethnicity prox-
ies (Bhopal and Donaldson,1998; Mays et al.,2003; Stronks et al.,
2009;Kagawa-Singeretal.,2010).InAmericanstudies,ethnicityis
often deﬁned as“self-deﬁned”race, which can also be interpreted
asanindividual’sculturalidentity(Maysetal.,2003;Schaueretal.,
2007; Kagawa-Singer et al., 2010). In certain European countries
where immigration is recent and most immigrants were born in
their country of “ethnic/cultural” origin, country of birth is usu-
allyusedasethnicity/culturalproxy(Stronksetal.,2009;Hempler
et al., 2010; Jenum et al., 2012). Our approach was to create a
morereﬁnedethnicityproxy,inattempttotakeculturallegacyinto
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account. The limitation of all methods mentioned above, is that
they do not take into account that ethnicity is one of many com-
ponents of culture and therefore insufﬁcient to fully understand
all cultural aspects involved in behavior- in this case adherence to
therapy (Schouten and Meeuwesen, 2006). However, it is beyond
the scope of this register-based,epidemiological study to embrace
other cultural parameters.
CONCLUSION
This study is the ﬁrst nationwide study which has investigated
the initiation of and persistence to warfarin treatment accord-
ing to ethnicity in patients with ﬁrst-time AF hospitalization. We
found that patients of Eastern and African origin with increased
thromboembolicriskdidnotinitiateadequatewarfarintreatment.
Furthermore,wheninitiated,thesepatientswerelesslikelytocon-
tinue treatment. Thus, this study found patients of African and
Eastern origin at increased risk of thromboembolic events com-
pared to patients of Danish and Western origin, despite equal
access to health care and medication. The hypothesis that ethnic
minorities are undertreated,generated by smaller studies in other
disease populations, is now supported by this nationwide study
performed by linking national registries on an individual basis.
Due to the retrospective and observational study design it was
not possible to establish direct causality, leaving future research
necessary in order to elucidate the underlying mechanisms that
explain differences in adherence to warfarin treatment among
ethnic groups. This is of paramount importance in an increas-
ingly globalized world. Furthermore, it is important that future
studies address, beyond ethnicity, all possible driving factors of
(non)initiation and persistence with treatment in general. This
will be particularly interesting in light of the new generation of
anticoagulants, which might render a very different adherence to
treatment.
Our results also showed markedly different thromboembolic
risk proﬁles and lower CHADS2 scores for patients of Eastern and
African origin, which could be due to the younger age of these
two subgroups. Since most previous AF studies rely on Caucasian
populationsfurtherresearchisneededtoexplorethesedifferences.
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